OLIGO Series

Nucleic acid drugs have gained significant attention in recent years as a highly promising area of new drug development. This Oligo series provide valuable insights into the development of oligonucleotide drugs, including challenges and strategies in DMPK research, in vitro and in vivo pharmacokinetic study design, metabolite identification, bioanalytical strategies, and the application of multiple quantitative bioanalysis methods. It also explores the ADME characteristics of FDA-approved siRNA drugs and antisense oligonucleotides (ASOs).